rich 1.0 Today's episode explores how FDA expedited pathways continue to shape advanced therapy development, from new RMAT designations for cell and gene therapies to an advisory committee review that underscores the agency's evolving expectations for clinical evidence. The BioPharm Brief https://audioboom.com/channels/5167274-the-biopharm-brief Audioboom https://audioboom.com 480 95 https://audioboom.com/i/43766076/600x600/c 600 600 <iframe width="100%" height="95" src="https://embeds.audioboom.com/posts/8933979/embed?v=202301" style="background-color: transparent; display: block; padding: 0; width: 100%" frameborder="0" allowtransparency="allowtransparency" scrolling="no" title="Audioboom player" allow="autoplay" sandbox="allow-downloads allow-forms allow-popups allow-same-origin allow-scripts allow-storage-access-by-user-activation allow-top-navigation-by-user-activation"></iframe>